Robert Daniel Levy
Research Subjects
Robert Daniel Levy has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Slaunwhite
BC Centre for Disease Control, Vancouver, Canada
1 shared publication Ana-Maria Bilawich
From the Department of Radiology, Division of Cardiothoracic Radiology (D.B., O.M.M., N.L.M., A.M.B.), Department of Medicine, Division of Respirology (R.G.N., R.D.L., C.B., J.R.S.), Department of Pathology (J.C.E.), and Department of Thoracic Surgery (J.Y.), Vancouver General Hospital, University of British Columbia, 899 W 12th Ave, Vancouver, BC, Canada V5Z 1L5; and British Columbia Lung Transplant Program, Vancouver, Canada (R.G.N., J.Y., R.D.L., C.B., J.R.S.).
1 shared publication- Caren Rose
British Columbia Centre for Disease Control Vancouver BC Canada
1 shared publication - Celine Bergeron
Centre for Lung Health, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
1 shared publication - Chak Keung Chan
King Abdullah University of Science and Technology (Jeddah, Saudi Arabia)
1 shared publication - Danielle Byrne
Division of Neuroradiology, Vancouver General Hospital, Vancouver, British Columbia, Canada
1 shared publication
Latest Publications
- 28 December 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (3) , e14866
Outcomes following heart or bilateral‐lung transplantation from donors who died of drug toxicity in British Columbia, Canada
Introduction: The illicit drug toxicity (overdose) crisis has worsened across Canada; between 2016 and 2021, more than 28,000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death (DTD) has increased in recent years. This study examines whether survival after heart or bilateral‐lung transplantation differed by donor cause of death.Methods: We studied transplant recipients in British Columbia who received heart (N = 110) or bilateral‐lung (N = 223) transplantation from deceased donors aged 12–70 years between 2013 and 2019. Transplant recipient survival was compared by donor cause of death from drug toxicity or other. Five‐year Kaplan‐Meier estimates of survival and 3‐year inverse probability treatment weighted Cox proportional hazards models were conducted.Results: DTD donors made up 36% (40/110) of heart and 24% (54/223) of bilateral‐lung transplantations. DTD donors were more likely to be young, white, and male. Unadjusted 5‐year recipient survival was similar by donor cause of death (heart: 87% for DTD and 86% for non‐DTD, p = .75; bilateral‐ lung: 80% for DTD and 76% for non‐DTD, p = .65). Adjusted risk of mortality at 3‐years post‐transplant was similar between recipients of DTD and non‐DTD donor heart (hazard ratio [HR]: .94, 95% confidence interval (CI): .22–4.07, p = .938) and bilateral‐lung (HR: 1.06, 95% CI: .41–2.70, p = .908).Conclusion: Recipient survival after heart or bilateral‐lung transplantation from DTD donors and non‐DTD donors was similar. Donation from DTD donors is safe and should be considered more broadly to increase organ donation.
- 28 December 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (3) , e14866
Outcomes following heart or bilateral‐lung transplantation from donors who died of drug toxicity in British Columbia, Canada
Introduction: The illicit drug toxicity (overdose) crisis has worsened across Canada; between 2016 and 2021, more than 28,000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death (DTD) has increased in recent years. This study examines whether survival after heart or bilateral‐lung transplantation differed by donor cause of death.Methods: We studied transplant recipients in British Columbia who received heart (N = 110) or bilateral‐lung (N = 223) transplantation from deceased donors aged 12–70 years between 2013 and 2019. Transplant recipient survival was compared by donor cause of death from drug toxicity or other. Five‐year Kaplan‐Meier estimates of survival and 3‐year inverse probability treatment weighted Cox proportional hazards models were conducted.Results: DTD donors made up 36% (40/110) of heart and 24% (54/223) of bilateral‐lung transplantations. DTD donors were more likely to be young, white, and male. Unadjusted 5‐year recipient survival was similar by donor cause of death (heart: 87% for DTD and 86% for non‐DTD, p = .75; bilateral‐ lung: 80% for DTD and 76% for non‐DTD, p = .65). Adjusted risk of mortality at 3‐years post‐transplant was similar between recipients of DTD and non‐DTD donor heart (hazard ratio [HR]: .94, 95% confidence interval (CI): .22–4.07, p = .938) and bilateral‐lung (HR: 1.06, 95% CI: .41–2.70, p = .908).Conclusion: Recipient survival after heart or bilateral‐lung transplantation from DTD donors and non‐DTD donors was similar. Donation from DTD donors is safe and should be considered more broadly to increase organ donation.
- 1 February 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (1) , e200314
Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings
Chronic lung allograft dysfunction may manifest with a spectrum of imaging and pathologic findings and a combination of obstructive and restrictive functional abnormalities. Awareness of the spectr... Chronic lung allograft dysfunction (CLAD) is the most common cause of mortality in lung transplant recipients after the 1st year of transplantation. CLAD has traditionally been classified into two ...
- 1 February 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (1) , e200314
Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings
Chronic lung allograft dysfunction may manifest with a spectrum of imaging and pathologic findings and a combination of obstructive and restrictive functional abnormalities. Awareness of the spectr... Chronic lung allograft dysfunction (CLAD) is the most common cause of mortality in lung transplant recipients after the 1st year of transplantation. CLAD has traditionally been classified into two ...
- Open Access
- 1 January 2014
- Published by Wiley in Canadian Respiratory Journal
- Vol. 21 (3) , 155-158
Dyspnea due to Pulmonary Vessel Arteritis
Pulmonary arteritis is a rare cause of pulmonary hypertension. Causes of pulmonary arteritis can be divided into primary and secondary, as well as classified according to vessel size. Only large vessel vasculitis is associated with pulmonary hypertension; primary forms include Takayasu arteritis and giant cell arteritis. The diagnosis of pulmonary arteritis can be challenging and the associated morbidity is serious without prompt, directed treatment. The authors present a case involving a 48‐year‐old First Nations man presenting with a six‐month history of exertional dyspnea and severe stenosis of the left pulmonary artery, who was ultimately diagnosed with pulmonary arteritis related to large vessel vasculitis.
- 1 January 2014
- Published by Wiley in Canadian Respiratory Journal
- Vol. 21 (3) , 155-158
Open AccessDyspnea due to Pulmonary Vessel Arteritis
Pulmonary arteritis is a rare cause of pulmonary hypertension. Causes of pulmonary arteritis can be divided into primary and secondary, as well as classified according to vessel size. Only large vessel vasculitis is associated with pulmonary hypertension; primary forms include Takayasu arteritis and giant cell arteritis. The diagnosis of pulmonary arteritis can be challenging and the associated morbidity is serious without prompt, directed treatment. The authors present a case involving a 48‐year‐old First Nations man presenting with a six‐month history of exertional dyspnea and severe stenosis of the left pulmonary artery, who was ultimately diagnosed with pulmonary arteritis related to large vessel vasculitis.
- 1 May 2010
- Published by Oxford University Press (OUP)
- p. A1500
The Hospital Burden Of COPD In Canada